ranibizumab
ranibizumab is listed in the FDA National Drug Code directory with 2 NDC codes. Available dosage forms: injection, solution, solution, concentrate.
Drug Details
- Generic Name
- ranibizumab
- Brand Names
- N/A
- Application Number
- Sponsor
- Patheon Italia S.p.A.
- NDC Codes
- 2
- Dosage Forms
- INJECTION, SOLUTION, SOLUTION, CONCENTRATE
- Routes
- N/A
- Active Ingredients
- RANIBIZUMAB
Indications and Usage
1 INDICATIONS AND USAGE BYOOVIZ is indicated for the treatment of patients with: BYOOVIZ, a vascular endothelial growth factor (VEGF) inhibitor, is indicated for the treatment of patients with: Neovascular (Wet) Age-Related Macular Degeneration (AMD) ( 1.1 ) Macular Edema Following Retinal Vein Occlusion (RVO) ( 1.2 ) Myopic Choroidal Neovascularization (mCNV) ( 1.3 ) 1.1 Neovascular (Wet) Age-Related Macular Degeneration (AMD) 1.2 Macular Edema Following Retinal Vein Occlusion (RVO) 1.3 Myopic Choroidal Neovascularization (mCNV)